The Children's Hospital of Zhejiang University School of Medicine

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

8 drugs in development

Phase 32

Phase 22

Phase 14

By Therapeutic Area

top 2

Immunology

225%

Metabolic & Endocrine

113%

R&D Momentum

58/100

Pipeline Velocity

39/100

Trial Completion Rate

75/100

Pipeline Concentration

47/100

Pipeline Freshness

83/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 11, 2026

Recruiting

Real-world Investigation of Diagnosis, Treatment, and Survival Status of Children With Ph+ ALL in China

Sep 9, 2026

Suspended

Clinical Study of CD19 Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Refractory Systemic Sclerosis

Earlier

Jun 30, 2026TrialA Clinical Study of the Safety, Efficacy, and Pharmacokinetics of Universal CD19/BCMA-Targeted CAR-T Cell Injection for the Treatment of Autoimmune Diseases in Children and Adolescents

Mar 19, 2026TrialExploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Mar 10, 2026TrialA Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

Mar 1, 2026TrialXenon Therapy for Children With Autism Spectrum Disorder

Mar 1, 2026TrialThe Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children

Feb 20, 2026TrialNUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy

4 more events

Feb 1, 2026TrialDexamethasone Regimens for BPD Prevention in Preterm Infants

Jan 13, 2026TrialSafety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV

Jan 1, 2026TrialTelitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis

Dec 3, 2025TrialExploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paediatric B Cell-related Autoimmune Diseases

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

KN5601Phase 1

Systemic Lupus Erythematosus

CD19 Universal CAR-T cellsPhase 2

Metabolic & Endocrine

Mucolipidosis Type IV

AAV9.hMCOLN1coPhase 1

Unknown / Other

Blinatumomab

Blinatumomab TreatmentPhase 1

CAR T Cell Therapy

anti-BCMA/CD70-CAR-T cellsPhase 1

Dexamethasone

Dexametasone. MediumPhase 3

Dexamethasone. DartPhase 3

Induction Chemotherapy

ZJCH-AML Standardized ChemotherapyPhase 2

Kidney

Blinatumomab TreatmentPhase 1

Refractory

anti-BCMA/CD70-CAR-T cellsPhase 1

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)